Lacosamide Ucb

Lacosamide, the active ingredient in Lacosamide Ucb, is an antiepileptic presented as an oral tablet for oral use. It is employed to treat partial‑onset seizures in patients with epilepsy, and may be used as adjunctive therapy when seizures are not adequately controlled by other medications.

GNH USA supplies Lacosamide Ucb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets and ensuring compliance with local regulatory requirements.

Lacosamide is an antiepileptic drug indicated for specific seizure types.

- Partial‑onset seizures: reduces the frequency of focal seizures when used alone or with other antiseizure medicines. - Adjunctive therapy in epilepsy: added to existing regimens to improve overall seizure control. - Focal seizures with secondary generalization: helps control seizures that spread from a focal origin.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue

Serious or Rare Side Effects: - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal thoughts or behavior - Liver function test elevations

When prescribing lacosamide, clinicians should consider several safety factors.

- Renal impairment: dose may need adjustment in patients with severe renal dysfunction. - Hepatic impairment: monitor liver function tests regularly. - Cardiac disease: avoid in patients with known conduction disorders. - Pregnancy: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lacosamide can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inducers (e.g., carbamazepine, phenytoin) may markedly reduce lacosamide levels. - Co‑administration with drugs that prolong the PR interval (e.g., class IA antiarrhythmics) can increase the risk of cardiac conduction delay.

Moderate Interactions (Monitor Closely): - Combination with other antiseizure medicines may increase central nervous system depression (e.g., benzodiazepines). - Concurrent use with alcohol may enhance dizziness and somnolence. - Use with drugs affecting renal excretion (e.g., probenecid) may alter lacosamide clearance.